treating kids news report

FDA Approves New Nonstimulant ADHD Medication from Supernus Pharmaceuticals

April 7, 2021Qelbree, a new nonstimulant medication for ADHD, has received FDA approval for treatment of attention deficit hyperactivity disorder in patients 6 to 17 years of age.

Qelbree is the first nonstimulant ADHD medication to receive FDA approval for use in children in more than a decade. Intuniv was the last branded, non-scheduled ADHD medication to be approved by the FDA in 2009.

Supernus plans to launch Qelbree in the U.S. in the second quarter, during back-to-school season for many families.Formerly known as SPN-812, Qelbree is a serotonin norepinephrine modulating agent.

The website is an aggregator of articles from open sources. The source is indicated at the beginning and at the end of the announcement. You can send a complaint on the article if you find it unreliable.

Related articles